At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to see if a lower dose of radiation therapy works as well as the standard dose in people with lymphoma. The people in this study have B-cell lymphoma that has not yet been treated.
-
The purpose of this study is to find the highest dose of the investigational drug NVL-655 that can be given safely in people with advanced non-small cell lung cancer (NSCLC) or other solid tumors that contain a genetic change called an ALK gene fusion. NVL-655 is a type of drug called a tyrosine kinase inhibitor (TKI), which works by blocking proteins that fuel cancer growth. However, some cancer cells develop resistance to TKI treatment.
-
Leiomyosarcoma is a type of cancer that forms in smooth muscle. Researchers want to see if adding ADI-PEG 20 to the usual chemotherapy for leiomyosarcoma works better than chemotherapy alone. The people in this study have leiomyosarcoma that keeps growing despite treatment.
-
The purpose of this study is to find the highest dose of the investigational drug BCA101 that can be given safely alone and in combination with the immunotherapy drug pembrolizumab in patients with advanced lung cancer that cannot be cured with standard treatments. BCA101 is an antibody that targets two proteins involved in cancer growth called EGFR and TGF-beta. By blocking these proteins, BCA101 may interfere with the signals that spur cancer growth. 
- A Phase 1/2 Study of DCC-3116 Plus Ripretinib for People with Advanced Gastrointestinal Stromal Tumor
Full Title A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies
Purpose
Researchers want to find the best dose of DCC-3116 to give with ripretinib for people with gastrointestinal stromal tumor (GIST). The people in this study have GIST that has spread, even with treatment.
Ripretinib is a standard treatment for GIST. It targets proteins that affect cancer growth, which may slow or stop cancer spread. DCC-3116 targets molecules that prevent tumor cells from recovering from the damage from other anti-cancer treatments, such as ripretinib. Both drugs are taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have GIST that has spread beyond its original location or to other parts of your body, even with treatment.
- Have completed prior GIST treatment at least 2 weeks before getting the study treatment.
- Not have had prior treatment with ripretinib.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Ping Chi’s office at 646-888-4166.
Protocol
23-353Phase
Phase I/II (phases 1 and 2 combined)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05957367ClinicalTrials.gov
-
The purpose of this study is to find the highest dose of the investigational drug RMC-6236 that can be given safely in people with advanced solid tumors containing mutations in the KRAS gene. RMC-6236 targets the KRAS protein made by the mutated gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of cancer cells. RMC-6236 is taken orally (by mouth).
-
In this study, researchers want to see how safe IDRX-42 is and how well it works to treat cancer. The people in this study have gastrointestinal stromal tumor (GIST) that keeps growing after treatment. In addition, their cancer has metastasized (spread) or is inoperable (cannot be taken out with surgery).
-
Researchers want to find the best dose of ABBV-453 to treat multiple myeloma. The people in this study have multiple myeloma that may have a genetic change and make too much of the BCL2 protein. In addition, their cancer has not responded to treatment or has returned after treatment.
-
Researchers are seeking the best dose of safusidenib erbumine to treat glioma that came back or keeps growing after treatment. The people in this study have glioma with a mutation (change or variant) in a gene called IDH1. Many gliomas have IDH1 mutations, which help cancer cells survive and grow.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.